388101-58-4
Chemical Structure
BMS-570520
- CAS No.: 388101-58-4
- Formula:C27H36FN5O3S
- Molecular Weight:529.67
InChIKey: ZFRLEPMXXGKKBN-WPFOTENUSA-N
SMILES: CC(C(SC(NC(N[C@H](CN(CC1)C(C)=O)[C@@H]1CN2C[C@@H](CCC2)CC3=CC=C(C=C3)F)=O)=N4)=C4C)=O
Biological Activity: BMS-570520 is an orally bioavailable CCR3 antagonist with an IC50 of 1.9 nM against hCCR3 and an IC50 of 1300 nM against hCYP2D6. BMS-570520 inhibits CYP2D6, but shows low activity against off-target G protein-coupled receptors, biogenic amine transporters, and the hERG potassium channel. BMS-570520 regulates chemotaxis, calcium mobilization, and anti-inflammatory pathways. BMS-570520 can be used in research related to asthma, allergic rhinitis, and contact dermatitis[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BMS-570520 | BMS-570520 is an orally bioavailable CCR3 antagonist with an IC50 of 1.9 nM against hCCR3 and an IC50 of 1300 nM against hCYP2D6. BMS-570520 inhibits CYP2D6, but shows low activity against off-target G protein-coupled receptors, biogenic amine transporters, and the hERG potassium channel. BMS-570520 regulates chemotaxis, calcium mobilization, and anti-inflammatory pathways. BMS-570520 can be used in research related to asthma, allergic rhinitis, and contact dermatitis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
